The association of CDKN2A ALT with reduced benefit from ICI therapy is found in urothelial carcinoma (UC), not in five other cancers: esophagogastric cancer, head and neck cancer, NSCLC, renal cell carcinomas, and melanoma [7]. Here, CDKN2A is linked to head and neck cancer.